Curriculum Vitae Dottoressa Fabiola Lorena Rojas. Dirigente Medico di Oncologia. Medico Oncologo-Borsista

Transcript

1 INFORMAZIONI PERSONALI Fabiola Lorena Rojas Nata il 07/06/1977 a Lima (Perù) ESPERIENZA PROFESSIONALE 12/12/2016-ad oggi Dirigente Medico di Oncologia 19/03/ /12/ /02/ /02/ /03/ /03/ /11/ /03/ /06/ /12/2015 Medico Oncologo Contratto di prestazione d opera professionale Titolo Progetto: "Conduzione di sperimentazioni cliniche sui tumori dell apparato gastrointestinale. Medico Oncologo-Borsista Borsa di Studio finanziata dalla Fondazione AIOM Titolo Progetto: "Infezione da HBV e HCV in pazienti affetti da tumori solidi da sottoporre a trattamento antineoplastico. Medico Oncologo Contratto di prestazione d opera professionale Titolo Progetto: "Valutazione dell'efficacia del modello assistenziale simultaneous care nel miglioramento della qualità di vita dei pazienti affetti da neoplasie maligne. Studio clinico controllato e randomizzato". Medico Oncologo Contratto di prestazione d opera professionale Titolo Progetto: Identificazione di parametri prognostici e predittivi di risposta alla chemioterapia e alle terapie biologiche. Introduzione di nuove metodiche di imaging nella scelta e programmazione del trattamento dei tumori solidi. Medico Oncologo - Guardia medica Varie Unità Operative (Angiologia, Oncologia, Ortopedia, Medicina Fisica e della Riabilitazione, Post Acuzie e Riabilitazione Estensiva-PARE) dell Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.. Contratto di prestazione d opera professionale 01/03/ /11/2011 Medico Oncologo Contratto di prestazione d opera professionale Titolo Progetto: Identification and clinical validation of predictive and prognostic factors, with special focus on molecular agents - conduzione di sperimentazioni cliniche sui tumori dello stomaco e del Unione europea, europass.cedefop.europa.eu Pagina 1 / 12

2 retto. 19/07/ /01/2005 Medico Contratto di prestazione d opera professionale Titolo Progetto: " monitoraggio di analisi dei risultati dei tumori del colon retto e dello stomaco. ISTRUZIONE E FORMAZIONE 03/12/2008 Specializzazione in Oncologia Medica Livello QEQ 8 Facoltà di Medicina e Chirurgia, dell'università degli Studi di Bologna Voto 70/70 e lode. II sessione /11/2003 Anno scolastico Abilitazione all esercizio della professione di Medico Chirurgo Università degli Studi di Palermo. Laurea in Medicina e Chirurgia Livello QEQ 6 Università degli Studi di Palermo. Voto 110/110 e menzione speciale Maturità Scientifica Livello QEQ 4 Liceo Scientifico Albert Einstein di Palermo COMPETENZE PERSONALI Lingua madre Spagnolo Altre lingue COMPRENSIONE PARLATO PRODUZIONE SCRITTA Ascolto Lettura Interazione Produzione orale Italiano C2 C2 C2 C2 C2 Inglese B2 B2 B2 B2 B2 FCE rilasciato da University of Cambridge- ESOL Examinations (English for Speakers of Others Languages), giugno Livelli: A1/A2: Utente base - B1/B2: Utente intermedio - C1/C2: Utente avanzato Quadro Comune Europeo di Riferimento delle Lingue ATTIVITÀ CLINICA L attività clinica prevalente, si è svolta in qualità di Oncologo prevalentemente presso il Day Hospital dedicato alla diagnosi e terapia di tumori solidi di pazienti con neoplasie del tratto gastroenterico (esofago, stomaco, fegato, pancreas,colon-retto,ano) e prevalente impegno in: -Conduzione di studi clinici controllati. -Gestione di pazienti in trattamento integrato chemio-radioterapico- Gestione di pazienti in trattamento locoregionale per metastasi epatiche. -Collaborazione con il programma di assistenza oncologica domiciliare e hospice per i pazient in fase avanzata di malattia -Trattamento e monitoraggio del dolore nel paziente oncologico. -Collaborazione col programma di assistenza psicologica ai pazienti e ai familiari. Dagli ultimi tre anni il Day hospital si occupa anche della diagnosi e terapia di tumori del distretto cervico-facciale con approccio multidisciplinare e conduzione di studi clinici controllati in qualità di sub-investigator. Unione europea, europass.cedefop.europa.eu Pagina 2 / 12

3 Attività clinica di diagnosi e follow-up nell'ambulatorio divisionale dedicato alle neoplasie gastroenteriche. Attività clinica di diagnosi, terapia e follow up nel Day Service di oncologia proctologica per il trattamento integrato dei tumori del retto e dell'ano Gestione clinica/programmazione terapeutica di pazienti con metastasi epatiche da adenocarcinoma del colon-retto suscettibili di approcci integrati (terapia sistemica,chirurgica e/o locoregionale) nell'ambito dei meeting del"gruppo multidisciplinare di studio per le metastasi epatiche". Consulenze specialistiche oncologiche nell'ambito dell'azienda ospedaliera. Attività clinica e di guardia medica nel reparto di degenza ordinaria e, fino al 2014 di guardie interdivisionali ( Angiologia, Oncologia, Ortopedia, Medicina Fisica e della Riabilitazione, Post Acuzie e Riabilitazione Estensiva-PARE). ATTIVITÀ DI RICERCA Impiego di nuove metodiche di imaging in funzione della predittività di risposta ai trattamenti con particolare riguardo all angiogenesi (18F-FDG-PET, ecografia epatica con mezzo di contrasto, RM epatica diffusion). Partecipazione e collaborazione attiva a gruppi di studio multidisciplinare per il trattamento integrato dei tumori del retto delle metastasi epatiche (raccolta dati, presentazione di casi clinici, pubblicazione di lavori) Caratterizzazione e valutazione biologica/molecolare in funzione dell utilizzo di terapie biologiche con anticorpi monoclonali in combinazione alla chemioterapia nel carcinoma gastrico. Valutazione dell impiego della 18F-FDG-PET come fattore prognostico e predittivo di risposta, con particolare orientamento al suo utilizzo nell ambito di trattamenti con terapie biologiche nel carcinoma gastrico. Partecipazione a comitati, gruppi di studio e società scientifiche nazionali e internazionali Dal 2004: Membro dell Associazione Italiana di Oncologia Medica (AIOM). Dal 2008: Membro di European Society of Medical Oncology (ESMO). 2008/2009: Partecipazione al progetto nazionale AIOM Farmaci ad alto costo, in collaborazione con AIOM giovani. 2009: Partecipazione al Tavolo di Lavoro AIOM AIOM-SIAPEC 2009: Partecipazione al Working Group Rapporti con Società Scientifiche e strategie integrate. Rapporti con i medici di medicina generale : Rappresentante regionale Giovani Oncologi al Consiglio Direttivo Regionale AIOM dell'emilia Romagna. Competenza digitale AUTOVALUTAZIONE Elaborazione delle informazioni Comunicazione Creazione di Contenuti Sicurezza Risoluzione di problemi Utente avanzato Utente avanzato Utente intermedio Utente avanzato Utente intermedio Livelli: Utente base - Utente intermedio - Utente avanzato Competenze digitali - Scheda per l'autovalutazione Patente di guida Categoria B Unione europea, europass.cedefop.europa.eu Pagina 3 / 12

4 PUBBLICAZIONI PER ESTESO Martoni AA, Pinto C, Di Fabio F, Lelli G, Rojas Llimpe FL, et al.: Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial). European Journal Cancer. 2006, 42 (18): Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, et al.: Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Annals of Oncology 2007; 18: Di Fabio F, Pinto C, Rojas Llimpe FL, et al.: The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab. Gastric Cancer 2007, 10: Vincenzi B, Santini D, Loupakis F, Addeo R, Rojas Llimpe FL, et al.: Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert Opinion On Biological Therapy 2009, 9(8): Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, et al.: Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal Cancer 2009, 101(8): Rojas Llimpe FL, Sara Pini.: I testi e le riviste scientifiche in Oncologia. In: Professione Oncologo (a cura di Carmine Pinto, Stefania Gori e Massimo Di Maio), capitolo 2 pagine 17-39, Il Pensiero Scientifico Editore Coautrice in: Guida all uso clinico dei biomarcatori in oncologia 2010 ( a cura di M. Gion, C. Trevisiol, S. Pregno, A.S.C. Fabricio). Biomedia, Milano, Adua D, Di Fabio F, Rojas Llimpe FL, et al: Long-term survival in an advanced gastric cancer patient treated with cetuximab in association with FOLFIRI: a case report. J Gastrointest Oncol (1):E13-7. Pinto C, Pini S, Di Fabio F, Cuicchi D, Iacopino B, Lecce F, Ercolani G, Rojas Llimpe FL, et al: Treatment strategy for rectal cancer with synchronous metastasis: 65 consecutive Italian cases from the Bologna Multidisciplinary Rectal Cancer Group. Oncology. 2014;86(3): Rojas Llimpe FL, et al: Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study. British Journal Cancer. Br J Cancer Aug 12;111(4): Lutrino SE, Bergamo F, Schirripa M, Rosati G, Avallone A, Giampieri R, Cordio S, Berretta M, Llimpe FR, et al: Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. Anticancer Res Apr;35(4): Fuccio L, Spada C, Frazzoni L, Paggi S, Vitale G, Laterza L, Mussetto A, Rojas F, et al: Higher adenoma recurrence rate after left- versus right-sided colectomy for colon cancer. Gastrointest Endosc. 2015;82(2): PARTECIPAZIONE A GRUPPI DI LAVORO MULTIDISCIPLINARE CON ESTENSIONE DI LINEE GUIDA Unione europea, europass.cedefop.europa.eu Pagina 4 / 12

5 1 Circulating tumor markers: a guide to their appropriate clinical use. Comparative summary of recommendations from clinical practice guidelines (PART 1). Int J Biol Markers 2016; 31(4): e332- e367. ABSTRACT PRESENTATI AI PRINCIPALI CONGRESSI NAZIONALI E INTERNAZIONALI Di Fabio F, Mini E, Gentile AL, Nobili S, Angelelli B, Giaquinta S, Rojas Llimpe FL, et al.: Evaluation of oxaliplatin (OXA) neurotoxicity in three advanced colorectal cancer (ACRC) consecutive studies. Proceedings World Congress on Gastrointestinal Cancer, June 2004 Barcelona, Spain, (Abstract p108). Di Fabio F, Mini E, Gentile AL, Nobili S, Angelelli B, Giaquinta S, Rojas Llimpe FL, et al.: Neurotoxiticity of oxaliplatin (OXA) in advanced colorectal cancer (ACRC) chemotherapy: Evaluation of three consecutive prospective studies. Annals of Oncology 2004; 6th National congress of Medical Oncology Proceedings. Vol 15, Supplement 2 (Abstract E4). Martoni A, Pinto C, Di Fabio F, Lelli G, Gentile AL, Rojas Llimpe FL, et al.: Phase II randomized trial on protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first line treatment in advanced colorectal cancer (ACRC): preliminary results of the Italian FOCA Study. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: Di Fabio F, Pinto C, Fanti S, Ceccarelli C, Gentile AL, Rojas Llimpe FL, et al.: Correlation between FDG-PET and pathologic response in patients with rectal cancer treated with neoadjuvant chemoradiotherapy: First Results of the Bologna Project. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: Pinto C, Ceccarelli C, Funaioli C, Mutri V, Rojas Llimpe FL, et al.: Prognostic value of KI-67, TS, P53, BCL-2, EGFR, MLH1 and MSH2 in 107 consecutive colorectal cancer patients. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: Sperandi F, Marino A, Pinto C, Melotti B, Mutri V, Rojas Llimpe FL, et al.: Uselessness of serous CA125 in clinical evaluation of malignant pleural mesothelioma (MPM). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: Gentile AL, Nanni C, Tardio ML, Rojas Limpe FL, et al.: FDG-PET and pathologic response in patients with rectal cancer treated with neoadjuvant chemo-radiotherapy: first results of the Bologna Project. Annals of Oncology 2005; 20th National GOIM Congress Proceedings. Vol 16, Supplement 4 (Abstract B5). Funaioli C, Pinto C, Ceccarelli C, Mutri V, Gentile AL, Rojas Llimpe FL, et al.: Bio-marker prognostic value in stage II-III of colorectal cancer. Annals of Oncology 2005; 7th National Congress of Medical Oncology Proceedings. Vol 16, Supplement 7 (Abstract D11). Di Fabio F, Gentile AL, Nanni C, Tardio ML, Cuicchi D, Rojas Llimpe FL, et al.: FDG-PET and pathological response in patients with rectal cancer treated with neoadjuvant chemoradiotherapy: first results of the Bologna Project. Annals of Oncology 2005; 7th National Congress of Medical Oncology Proceedings. Vol 16, Supplement 7 (Abstract D13). Pinto C, Di Fabio F, Gentile AL, Mini E, Giaquinta S, Rojas Llimpe FL, Mutri V, Piana E, Mazzei T, Unione europea, europass.cedefop.europa.eu Pagina 5 / 12

6 Martoni A: Advanced colorectal cancer (ACRC) in elderly patients: evaluation of three different oxaliplatin-based chemotherapy regimens. Annals of Oncology 2005; 7th National Congress of Medical Oncology Proceedings. Vol 16, Supplement 7 (Abstract D28). Martoni A, Pinto C, Di Fabio F, Lelli G, Rojas Llimpe FL, et al.: Protracted 5-fluorouracil infusion plus oxaliplatin (FOX) versus capecitabine plus oxaliplatin (XELOX) as first-line treatment in advanced colorectal cancer (ACRC): Preliminary results of the Italian phase II FOCA Study. Annals of Oncology 2005; 7th National Congress of Medical Oncology Proceedings. Vol. 16, Supplement 7 (Abstract D30). Pinto C, Di Fabio F, Siena S, Rojas Llimpe FL, et al.: Phase II study of cetuximab in combination with FOLFIRI as first-line treatment in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX Study): Preliminary results. Proceedings of 2006 Gastrointestinal Cancers Symposium, abstract n 65. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, et al.: Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: Di Fabio F, Pinto C, Fanti S, Rojas Llimpe FL, et al.: 18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian FOLCETUX Study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: Di Fabio F, Pinto C, Fanti S, Rojas Llimpe FL, et al.: Positron emission tomography (18FDG-PET) in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian Phase II Study. Annals of Oncology 2006 World Congress on Gastrointestinal Cancer Proceedings. Vol. 17, Supplement 6 (Abstract P247). Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, et al.: Cetuximab in combination with FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastrooesophageal junction (GEJ) adenocarcinoma: Preliminary results of the Italian Phase II Study. Annals of Oncology 2006 World Congress on Gastrointestinal Cancer Proceedings. Vol. 17, Supplement 6 (Abstract P268). Cerea G, Sartore-Bianchi A, Veronese S, Andreotti IC, Di Fabio F, Funaioli C, Rojas Llimpe FL, et al.: EGFR copy number and clinical outcome to cetuximab + FOLFIRI regimen (FOLCETUX) in first-line treatment of metastatic and locally advanced gastric cancer. Annals of Oncology 2006; 31st ESMO Congress Proceedings. Vol. 17, Supplement 9 (Abstract 852P). Di Fabio F, Pinto C, Siena S, Cascinu S, Ceccarelli C, Rojas Llimpe FL, et al.: Cetuximab in combination with FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results of FOLCETUX Phase II Study. Annals of Oncology 2006; 31st ESMO Congress Proceedings. Vol. 17, Supplement 9 (Abstract 1077P). Funaioli C, Pinto C, Di Fabio F, Rojas Llimpe FL, et al.: Impact of metastasectomy in patients with advanced colorectal cancer (ACRC): Evaluation of 41 consecutive cases. Annals of Oncology 2006; 8th National Congress of Medical Oncology Proceedings. Vol. 17, Supplement 11 (Abstract D9). Rojas Llimpe FL, Di Fabio F, Pinto C, et al.: Karnofsky Performance Status (KPS) and CEA levels at diagnosis of advanced colorectal cancer (ACRC) may predict patients who will be able to receive a second-line chemotherapy. Annals of Oncology 2006; 8th National Congress of Medical Oncology Proceedings. Vol. 17, Supplement 11 (Abstract D21). Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, et al.: Phase II Study of cetuximab in combination with folfiri as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: Preliminary results (FOLCETUX Study). Annals of Oncology 2006; 8th National Congress of Medical Oncology Proceedings. Vol. 17, Supplement 11 (Abstract E25). Unione europea, europass.cedefop.europa.eu Pagina 6 / 12

7 Castellucci P, Ambrosiani V, Nanni C, Di Fabio F, Pinto C, Rojas Llimpe FL, et al: Preliminary results of the Italian Folcetux study: Early evaluation of treatment with 18FDG PET in gastric or gastroesophageal junction adenocarcinoma. The Journal of Nuclear Medicin 2006, 47 (Supplement 1): 229P- Oral Presentation. Rojas Llimpe FL, Di Fabio F, Ceccarelli C, et al.: Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: Funaioli C, Pinto C, Ceccarelli C, Di Fabio F, Cuicchi D, Rojas Llimpe FL, et al.: Prognostic significance of pathological biomarkers in patients with stage II-III colorectal cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: Di Fabio F, Pinto C, Rojas Llimpe FL, et al.: Exploring the predictive value of early 18F-FDG PET evaluation during treatment with cetuximab plus chemotherapy for advanced gastric or gastroesophageal adenocarcinoma. Annals of Oncology of 2007 World Congress on Gastrointestinal Cancer. Vol 18. Supplement 7 (Abstract P-0239). Rojas Llimpe FL, Di Fabio F, Pinto C, et al.: Pathologic biomarker analysis in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab in combination with chemotherapy. Annals of Oncology 2007; 9th National Congress of Medical Oncology. Vol 18, Supplement 11 (Abstract A3). Funaioli C, Pinto C, Di Fabio F, Malavasi N, Mutri V, Rojas Llimpe FL, et al.: Correlation between anti-egfr monoclonal antibodies in the treatment of gastrointestinal cancer and electrolytic imbalance. Annals of Oncology 2007; 9th National Congress of Medical Oncology. Vol 18, Supplement 11 (Abstract A13). Di Fabio F, Pinto C, Rojas Llimpe FL, et al.: The predictive role of 18F-FDG-PET early evaluation in patients treated with cetuximab plus chemotherapy for advanced gastric or gastroesophageal adenocarcinoma. Annals of Oncology 2007; 9th National Congress of Medical Oncology. Vol 18, Supplement 11 (Abstract A80). Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Rojas Llimpe FL, et al.: Phase II study of cetuximab in combination with cisplatin/docetaxel as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (DOCETUX Study): Preliminary results. Proceedings of 2008 Gastrointestinal Cancers Symposium, abstract n 34. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Rojas Llimpe FL, et al.: Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian Phase II DOCETUX Study). J Clin Oncol 26: 2008 (May 20 suppl; abstr 4575) ASCO Annual Meeting Funaioli C, Pinto C, Di Fabio F, Malavasi N, Di Tullio P, Pini S, Vincenzi B, Rojas Llimpe FL, et al.: Evaluation of electrolytic imbalance in patients with advanced colorectal and gastric cancer treated with anti-egfr monoclonal antibody-based therapy. J Clin Oncol 26: 2008 (May 20 suppl; abstr 14631) ASCO Annual Meeting Di Fabio F, Pinto C, Bucca E, Giaquinta S, Fabricio A, Mutri V, Michilin S, Rojas Llimpe FL, et al.: Predictive value of circulating VEGF in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin and docetaxel (Italian phase II DOCETUX Study). J Clin Oncol 26: 2008 (May 20 suppl; abstr 15605) ASCO Annual Meeting Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Rojas Llimpe FL, et al.: Phase II study of cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology 2008, ESMO International Symposium: 10th World Congress on Gastrointestinal Cancer Proceedings. Vol 19. Supplement 6 (Abstract O-002). Unione europea, europass.cedefop.europa.eu Pagina 7 / 12

8 Di Tullio P, Di Fabio F, Rojas Llimpe FL, et al.: Evaluation and management of skin toxicity in patients with advanced gastrointestinal cancer treated with anti-egfr monoclonal antibodies (a prospective monocentric study). Annals of Oncology 2008, 10th National Congress of Medical Oncology Proceedings. Vol. 19, Supplement 9 (Abstract B8). Di Fabio F, Pinto C, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, et al.: Cetuximab with cisplatin and docetaxel as first-line treatment in patients with locally advanced/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma ( Italian phase II docetux Study). Annals of Oncology 2008, 10th National Congress of Medical Oncology Proceedings. Vol. 19, Supplement 9 (Abstract G2). Rojas Llimpe FL, Di Fabio F, Castellucci P, et al.: Early metabolic response evaluation by 18F-FDG- PET in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian Docetux Study. Annals of Oncology 2008, 10th National Congress of Medical Oncology Proceedings. Vol. 19, Supplement 9 (Abstract G10). Vincenzi B, Loupakis F, Santini D, Rojas Llimpe FL, et al.: Cigarettes smoking habit may induce a reduced efficacy of cetuximab-based treatment in advanced colorectal cancer patients. Annals of Oncology 2008, 10th National Congress of Medical Oncology Proceedings. Vol. 19, Supplement 9 (Abstract H33). Mutri V, Bucca E, Giaquinta S, Pinto C, Di Fabio F, Fabricio A, Michilin S, Rojas Llimpe FL, et al.: Predictive value of circulating E-selectin in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin and docetaxel (Italian Phase II DOCETUX Study). Annals of Oncology 2008, 10th National Congress of Medical Oncology Proceedings. Vol. 19, Supplement 9 (Abstract M5). Stella G, Rojas Llimpe FL, Barone C, et al.: KRAS and BRAF mutational status and response to cetuximab combination therapy in advanced gastric cancer (GC) patients. Proceedings of 2009 Gastrointestinal Cancers Symposium, abstract n 34. Rojas Llimpe FL, Di Fabio F, Ercolani G, et al.: Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study). Journal of Clinical Oncology 27, 2009 (suppl; abstr e15010) ASCO Annual Meeting Stella G, Rojas Llimpe FL, Barone C, et al.: KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. Journal of Clinical Oncology 27, 2009 (suppl; abstr e15503) ASCO Annual Meeting Di Fabio F, Pinto C, Rojas Llimpe FL, et al.: Early predictive value of 18F-FDG-PET assessment in advanced esophagogastric junction and gastric cancer patients treated with cetuximab-containing therapy. Journal of Clinical Oncology 27, 2009 (suppl; abstr e15601) ASCO Annual Meeting Rojas Llimpe FL, Di Fabio F, Ercolani G, et al.: Comparative imaging evaluation before surgical resection of liver metastasis in colorectal cancer patients: First results of Italian Prometeo Study. Annals of Oncology 2009; ESMO International Symposium: 11th World Congress on Gastrointestinal Cancer Proceedings. Vol 20. Supplement 7 (Abstract PD-0019). Di Fabio F, Pinto C, Rojas Llimpe FL, et al.: Evaluation of early predictive 18F-FDG-PET assessment in advanced esophagogastric junction and gastric cancer patients treated with cetuximab containing therapy. Annals of Oncology 2009; ESMO International Symposium: 11th World Congress on Gastrointestinal Cancer Proceedings. Vol 20. Supplement 7 (Abstract PD-0034). Giaquinta S, Bucca E, Mutri V, Di Fabio F, Rojas Llimpe FL, et al.: E-Selectin and vascular endothelial growth factor (VEGF) evaluation in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin and docetaxel (Italian phase II Docetux study): Final Results. Annals of Oncology 2009; 11th National Congress of Medical Oncology Proceedings. Vol 20. Supplement 8 (Abstract D4*-Oral Presentation). Rojas Llimpe FL, Di Fabio F, Ercolani G, et al.: Prospective study on pre-operative diagnostic accuracy of different imaging techniques in colorectal cancer patients with liver metastases candidates to surgical resection (Italian PROMETEO Study). Annals of Oncology 2009; 11th National Unione europea, europass.cedefop.europa.eu Pagina 8 / 12

9 Congress of Medical Oncology Proceedings. Vol 20. Supplement 8 (Abstract L19- Poster). Pini S, Di Fabio F, Pinto C, Rojas Llimpe FL et al.: New onco-geriatric screening test for gastrointestinal cancer in elderly patients. Preliminary data. Annals of Oncology 2009; 11th National Congress of Medical Oncology Proceedings. Vol 20. Supplement 8 (Abstract L61). Rojas Llimpe FL, Di Fabio F, Ercolani G, et al.: Presurgical diagnostic accuracy of five imaging procedures in chemotherapy-naive (group A) or chemotherapy-pretreated (group B) patients with colorectal liver metastases (Italian PROMETEO Study). Journal of Clinical Oncology 28:15s, 2010 (suppl; abstr 3621). ASCO Annual Meeting General Poster Session. Pinto C, Mutri V, Di Fabio F, Giaquinta S, Ceccarelli C, Rojas Llimpe FL, et al.: Analysis of biomarker expression (ki67, EGFR, HER2, ERK, NFkB, and mtor) in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated with cetuximab plus cisplatin/docetaxel: DOCETUX study. Journal of Clinical Oncology 28:15s, 2010 (suppl; abstr 4133). ASCO Annual Meeting General Poster Session. Rojas Llimpe FL, Di Fabio F, Ercolani G, et al.: Diagnostic accuracy of five imaging procedures before surgery in chemo-nai ve (group a) or chemo-pretreated (group b) patients with colorectal liver metastases (Italian PROMETEO study). Annals of Oncology 2010; ESMO International Symposium: 12th World Congress on Gastrointestinal Cancer Proceedings. Vol 21. Supplement 6 (Abstract Poster-0172). Rojas Llimpe FL, Di Fabio F, Fiorentino M, et al.: Evaluation of KRAS, BRAF and PI3KCA in synchronous and metachronous metastatic colorectal cancer (MCRC). Annals of Oncology 2010, ESMO Congress, 8-12 October 2010, Vol 21, Supplement 8 (Abstract 594P- General Poster session). Rojas Llimpe FL, Di Fabio F, Ercolani G, et al.: Accuracy of imaging procedures before liver surgery in patients with upfront colorectal liver metastases or after chemotherapy (Italian Prometeo Study). Tumori 2010; XII National Congress of Medical Oncology, Proceedings. Vol 10, Number 1, October 2010 (Abstract A17-Genral Poster Session). Sartore-Bianchi A, Funaioli C, Artale S, Dettori M, Pinto C, Zamboni F, Cipani T, Sarnataro CS, Lauricella C, Rojas Llimpe FL, et al.: Molecular alterations of colorectal cancer in patients long-term survivors after metastasectomy. Tumori 2010; XII National Congress of Medical Oncology, Proceedings. Vol 10, Number 1, October 2010 (Abstract A43). Di Fabio F, Pinto C, Mutri V, Ceccarelli C, Giaquinta S, Rojas Llimpe FL, et al.: Biomarker analysis in patients with advanced gastric and gastroesophageal junction (GEJ) cancer treated in phase II study with cetuximab plus cisplatin/doceaxel (Docetux Study). Tumori 2010; XII National Congress of Medical Oncology, Proceedings. Vol 10, Number 1, October 2010 (Abstract H4-Oral communication). Pinto C, Barone C, Martoni A, Di Tullio P, Orlandi A, Di Fabio F, Cassano A, Rojas Llimpe FL, et al.: Vitamin K1 cream in the management of skin rash during anti-egfr monoclonal antibody (mab) treatment in patients with metastatic cancer: First analysis of an observational Italian study. J Clin Oncol 29: 2011 (suppl 4; abstr 594) Gastrointestinal Cancers Symposium: General Poster Session C. Mutri V, Pinto C, Giaquinta S, Di Tullio P, Torri V, Melotti B, Sperandi S, Di Fabio F, Rojas Llimpe FL, et al.: Phase I study of sorafenib and cisplatin/pemetrexed regimen in untreated malignant pleural mesothelioma (MPM) patients (Italian SoMe Study). J Clin Oncol 29: 2011 (suppl; abstr 7087) ASCO Annual Meeting: General Poster Session, Lung Cancer - Local-regional and Adjuvant Therapy/Small Cell. Pinto C, Barone C, Ferrari D, Di Tullio P, Latiano TP, Orlandi A, Di Fabio F, Cassano A, Rojas Llimpe FL, et al: Topical vitamin K1 in the management of skin rash during anti-egfr monoclonal antibody treatment in patients with metastatic cancer: Italian Observational Study. J Clin Oncol 29: 2011 (suppl; abstr e14068) ASCO Annual Meeting. Pinto C, Barone C, Di Fabio F, Ferrari D, Di Tullio P, Latiano T, Orlandi A, Cassano A, Rojas Llimpe FL, et al: Management of skin rash with topical vitamin K1during anti-egfr monoclonal antibody Unione europea, europass.cedefop.europa.eu Pagina 9 / 12

10 treatment (Italian observational Study). Annals of Oncology 2011; ESMO International Symposium: 13th World Congress on Gastrointestinal Cancer Proceedings. Vol 22. Supplement 5 (Abstract Poster-0374). Pini S, Pinto C, Di Fabio F, Di Tullio P, Cuicchi D, Lecce F, Golfieri R, Ugolini G, Iacopino B, Rojas Llimpe FL, et al: Concordance between RM and CT/EUS staging in locally advanced rectal cancer (LARC): A Bologna multidisciplinary rectal cancer group experience. TUMORI, a Journal of Experimental and Clinical Oncology 11(2), October 2011 (abstract E9). XIII Congresso Nazionale di Oncologia Medica. General Poster Session. Di Fabio F, Pinto C, Pini S, Di Tullio P, Cuicchi D, Iacopino B, Lecce F, Ugolini G, Ercolani G, Stella F, Rojas Llimpe FL, et al: Treatment of advanced rectal cancer with synchronous metastasis at diagnosis: Analysis of 63 consecutive cases of the Bologna multidisciplinary rectal cancer group. TUMORI, a Journal of Experimental and Clinical Oncology 11(2), October 2011 (abstract E11). XIII Congresso Nazionale di Oncologia Medica. General Poster Session. Di Tullio, Barone C, Pinto C, Ferrari D, Latiano T, Orlandi A, Fabio F, Cassano A, Rojas Llimpe FL, et al: Topical vitamin K1 in the management of skin rash during anti-egfr monoclonal antibody treatment in patients with metastatic cancer (Italian Observational study). TUMORI, a Journal of Experimental and Clinical Oncology 11(2), October 2011 (abstract E12). XIII Congresso Nazionale di Oncologia Medica. General Poster Session Rojas Llimpe FL, et al: Impact of PET scan in detecting extrahepatic disease in potentially resectable colorectal cancer liver metastasis patients. TUMORI, a Journal of Experimental and Clinical Oncology 11(2), October 2011 (abstract E17). XIII Congresso Nazionale di Oncologia Medica. General Poster Session. Pinto C, Pini S, Di Fabio F, Cuicchi D, Iacopino B, Lecce F, Ercolani G, Rojas Llimpe FL, et al: Treatment of rectal cancer with synchronous metastasis at diagnosis: 65 consecutive Italian cases of the Bologna Multidisciplinary Rectal Cancer Group. Journal of Clinical Oncology 30, 2012 (suppl 4; abstr 676) Gastrointestinal Cancers Symposium- General Poster Session C: Cancers of the Colon and Rectum. Lutrino SE, Schirripa M, Calvetti l, Rosati G, Giampieri R, Avallone A, Cordio SS, Berretta M, Rojas Llimpe FL, et al: Should bevacizumab (B) be included in the first-line treatment of elderly patients with advanced colorectal cancer (CRC)- Results from a community-based Italian observational study. Journal of Clinical Oncology 30, 2012 (suppl; abstr e14040) ASCO Annual Meeting- Online publication. Pini S, Ceccarelli C, Di Fabio F, Iacopino B, Lecce F, Ugolini G, Varrese F, Rojas Llimpe FL, et al: Annals of Oncology 23 (Supplement 4): iv31 iv118, ESMO 14th World Congress on Gastrointestinal Cancer, June 2012, Barcelona, Spain: Poster Session (p0297). Rojas Llimpe F.L., et al: Neoadjuvant Chemoradiotherapy (CRT) in elderly and young patients with locally advanced rectal cancer (LARC): Bologna multidisciplinary rectal cancer group STUDY (BMRG-C01). TUMORI, a Journal of Experimental and Clinical Oncology 13 (3), October 2012 (abstract B14). XIV Congresso Nazionale di Oncologia Medica. General Poster Session. Pini S, Di Fabio F, Ceccarelli C, Iacopino B, Lecce F, Ugolini G, Varrese F, Rojas Llimpe FL, et al: Predictive and prognostic value of clinical and pathological factors in locally advanced rectal cancer (LARC) patients treated with neoadjuvant chemoradiotherapy (CRT): Bologna multidisciplinary rectal cancer group study (BMRG-B01-STUDY). TUMORI, a Journal of Experimental and Clinical Oncology 13 (3), October 2012 (abstract B15). XIV Congresso Nazionale di Oncologia Medica. General Poster Session. Di Fabio F, Rojas Llimpe FL, et al: Management of patients with colorectal liver metastases: results of bologna multidisciplinary team (MDT) experience. TUMORI, a Journal of Experimental and Clinical Oncology 13 (3), October 2012 (abstract B32). XIV Congresso Nazionale di Oncologia Medica. General Poster Session. Ferrari L, Schirripa M, Calvetti L, Rosati G, Gianpieri R, Avallone A, Cordio S, Berretta M, Rojas Llimpe FL, et al: Bevacizumab (B) combined to chemotherapy for first-line treatment of elderly patients with advanced colorectal cancer (CRC): results from a large community-based Italian Unione europea, europass.cedefop.europa.eu Pagina 10 / 12

11 observational study. TUMORI, a Journal of Experimental and Clinical Oncology 13 (3), October 2012 (abstract B35). XIV Congresso Nazionale di Oncologia Medica. Pini S, Di Fabio F, Ceccarelli C, Iacopino B, Lecce F, Cuicchi D, Ugolini G, Varrese F, Guido A, Rojas Llimpe FL, et al: Analysis of predictive and prognostic value of clinical and pathological factors in locally advanced rectal cancer (LARC) treated with neoadjuvant chemoradiotherapy (CRT): Bologna multidisciplinary rectal cancer group study (BMRG-B01-Study). Journal of Clinical Oncology 30: 2012 (suppl 34; abstr 421) Gastrointestinal Cancers Symposium- General Poster Session C: Cancers of the Colon and Rectum. Rojas Llimpe FL, et al: Clinical impact of first response evaluation (FRE) in metastatic colorectal cancer (mcrc) patients (pts) treated with a cetuximab-based regimen (C-R): Results of a monoinstitutional experience. Journal of Clinical Oncology 31, 2013 (suppl; abstr e14717) ASCO Annual Meeting- Online pubblication. Pini S, Di Fabio F, Iacopino B, Guido A, Castellucci P, Cuicchi D, Fanti S, Lecce F, Rojas Llimpe FL, et al: Prognostic value of baseline 18F-FDG-PET (PET) in anal cancer (AC) patients (pts): A Bologna Multidisciplinary Rectal Cancer Group analysis (BMRCG-AC01). Journal of Clinical Oncology 31, 2013 (suppl; abstr e15154) ASCO Annual Meeting - Online pubblication. 73 Adua D, Altimari A, Gruppioni E, Ercolani G, Rojas Llimpe FL, et al: Molecular evaluation of primary tumor (PT) and synchronous liver metastasis in colorectal cancer (srlmcrc) patients after cetuximab-based chemotherapy ASCO Annual Meeting; General Poster Session, Gastrointestinal (Colorectal) Cancer. Rojas Llimpe FL, et al: HCV/HBV infection in Italian patients (pts) with solid tumor candidates for chemotherapy (CT) ASCO Annual Meeting Pinto C, Mosconi C, Angelelli B, Mutri V, Giampalma E, Cappelli A, Monari F, Pettinato C, Levorato M, Giaquinta S, Di Fabio F, Rojas Llimpe FL, et al: Efficacy of yttrium-90 (Y90) radioembolization in patients with chemorefractory colorectal cancer (CRC) liver metastasis: Results of Bologna study ASCO Annual Meeting. C Cremolini, F Loupakis, L Salvatore, S Lonardi, F Battaglin, T Gamucci, R Grande, F Di Fabio, F L Rojas Llimpe, et al. Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mcrc) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group. J Clin Oncol 32:5s, 2014 (suppl; abstr 3596). Adua D A, Atimari A, Gruppioni E, Ercolani G, Rojas Llimpe FL, et al: Detention of molecular changes between primary tumor (PT) and synchronous resected liver metastases (SRLM) in colo-rectal cancer (CRC) patients after first line cetuximab based chemotherapy (CT). Ann Oncol (2014) 25 (suppl 2): ii6, ESMO 16th World Congress on Gastrointestinal Cancer, June 2014, Barcelona, Spain, Poster presentation and poster oral discussion (P-0181). Rojas LlimpeF.L., et al: HCV and HBV infection in italian patients with solid tumor candidates for chemotherapy (ct) treatment; I supplementi di Tumori : Volume 15, Number 1, October 2014, Poster - XVI National congress of medical oncology. Adua D., Altimari A.,Gruppioni E., Ercolani G., Rojas Llimpe F.L., al.:molecular heterogeneity among primary tumour (pt) and synchronous resected liver metastasis (srlm) in colorectal cancer (crc) patients after cetuximab-based chemotherapy; I supplementi di Tu-mori :Volume 15, Number 1, October 2014, Poster - XVI National congress of medical oncology. Cirillo M., Carlucci L., Pacchetti I., Rulli E., Sacco C., Zagonel V., Baldini E., Rojas Llimpe F.L., et al.: Oral Anticancer Therapy Project: clinical utility of a specific home care nursing program. J Clin Oncol 34, 2016 (suppl; abstr 6597). Cremolini C., Antoniotti C., Loupakis F., Bergamo F., Ferrari L., Grande R., Tonini G., Masi G., Schirripa M., Bonotto M., Soldà C., Lucchesi S., Rossini D., Corsi D., Ronzoni M., Rojas Llimpe F.L., et al: Modified FOLFOXIRI (mfolfoxiri) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mcrc): The phase II randomized Unione europea, europass.cedefop.europa.eu Pagina 11 / 12

12 MACBETH trial by GONO. Annals of Oncology 27 (Supplement 6): vi1 vi14, Antoniotti C., Cremolini C., Loupakis F., Bergamo F., Garattini S., Grande R., Tonini G., Masi G., Schirripa M., Bonotto M., Rumanò L., Lucchesi S., Rossini D., Corsi D., Ronzoni M., Rojas Llimpe FL., et al: Modified FOLFOXIRI (mfolfoxiri) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mcrc): the phase II randomized MACBETH trial by GONO. Annals of Oncology 27 (Supplement 4): iv107 iv125, 2016.m.- Plenary Session. Cirillo M., Carlucci L., Baldini E., Sacco C., Zagonel V., Leo S., Rojas Llimpe F.L., et al: Oral Anticancer Therapy Project: clinical utility of a specific home care nursing program. Annals of Oncology 27 (Supplement 4): iv107 iv125, 2016 (S02). La sottoscritta FABIOLA LORENA ROJAS, consapevole delle conseguenze penali in caso di dichiarazioni mendaci, sotto la propria personale responsabilità dichiara di possedere le sottoindicate esperienze formative e professionali indicate nel presente curriculum vitae. Bologna 21/02/2017 Unione europea, europass.cedefop.europa.eu Pagina 12 / 12